Literature DB >> 25758237

[Intratumoral heterogeneity in renal cell carcinoma. Molecular basis and translational implications].

R Höfflin1, W Roth, H Sültmann, C Grüllich, G Hatiboglu, J Nyarangi-Dix, G Schönberg, D Teber, B Hadaschik, S Pahernik, M Hohenfellner, S Duensing.   

Abstract

Advanced clear cell renal cell carcinoma is characterized by extensive intratumoral genomic heterogeneity and branched as well as convergent evolutionary traits with genomically different subclones evolving in parallel in the same tumor. Distinct driver mutations can be found in spatially separated subclones, which may hinder the development of novel targeted therapies. However, truncal mutations of the VHL tumor suppressor gene and chromosome 3p loss were ubiquitously detected and will hence continue to be a focus of future drug development. Nevertheless, genomic instability, enhanced tumor genome plasticity and intratumoral heterogeneity are likely to represent major challenges towards biomarker development and personalized patient care.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25758237     DOI: 10.1007/s00120-015-3800-9

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  7 in total

Review 1.  Genetic instability and darwinian selection in tumours.

Authors:  D P Cahill; K W Kinzler; B Vogelstein; C Lengauer
Journal:  Trends Cell Biol       Date:  1999-12       Impact factor: 20.808

2.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Authors:  Brian I Rini; Bernard Escudier; Piotr Tomczak; Andrey Kaprin; Cezary Szczylik; Thomas E Hutson; M Dror Michaelson; Vera A Gorbunova; Martin E Gore; Igor G Rusakov; Sylvie Negrier; Yen-Chuan Ou; Daniel Castellano; Ho Yeong Lim; Hirotsugu Uemura; Jamal Tarazi; David Cella; Connie Chen; Brad Rosbrook; Sinil Kim; Robert J Motzer
Journal:  Lancet       Date:  2011-11-04       Impact factor: 79.321

3.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

4.  Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.

Authors:  Marco Gerlinger; Stuart Horswell; James Larkin; Andrew J Rowan; Max P Salm; Ignacio Varela; Rosalie Fisher; Nicholas McGranahan; Nicholas Matthews; Claudio R Santos; Pierre Martinez; Benjamin Phillimore; Sharmin Begum; Adam Rabinowitz; Bradley Spencer-Dene; Sakshi Gulati; Paul A Bates; Gordon Stamp; Lisa Pickering; Martin Gore; David L Nicol; Steven Hazell; P Andrew Futreal; Aengus Stewart; Charles Swanton
Journal:  Nat Genet       Date:  2014-02-02       Impact factor: 38.330

5.  Tumor clone dynamics in lethal prostate cancer.

Authors:  Suzanne Carreira; Alessandro Romanel; Jane Goodall; Emily Grist; Roberta Ferraldeschi; Susana Miranda; Davide Prandi; David Lorente; Jean-Sebastien Frenel; Carmel Pezaro; Aurelius Omlin; Daniel Nava Rodrigues; Penelope Flohr; Nina Tunariu; Johann S de Bono; Francesca Demichelis; Gerhardt Attard
Journal:  Sci Transl Med       Date:  2014-09-17       Impact factor: 17.956

6.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.

Authors:  Ignacio Varela; Patrick Tarpey; Keiran Raine; Dachuan Huang; Choon Kiat Ong; Philip Stephens; Helen Davies; David Jones; Meng-Lay Lin; Jon Teague; Graham Bignell; Adam Butler; Juok Cho; Gillian L Dalgliesh; Danushka Galappaththige; Chris Greenman; Claire Hardy; Mingming Jia; Calli Latimer; King Wai Lau; John Marshall; Stuart McLaren; Andrew Menzies; Laura Mudie; Lucy Stebbings; David A Largaespada; L F A Wessels; Stephane Richard; Richard J Kahnoski; John Anema; David A Tuveson; Pedro A Perez-Mancera; Ville Mustonen; Andrej Fischer; David J Adams; Alistair Rust; Waraporn Chan-on; Chutima Subimerb; Karl Dykema; Kyle Furge; Peter J Campbell; Bin Tean Teh; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2011-01-19       Impact factor: 49.962

7.  Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.

Authors:  Gillian L Dalgliesh; Kyle Furge; Chris Greenman; Lina Chen; Graham Bignell; Adam Butler; Helen Davies; Sarah Edkins; Claire Hardy; Calli Latimer; Jon Teague; Jenny Andrews; Syd Barthorpe; Dave Beare; Gemma Buck; Peter J Campbell; Simon Forbes; Mingming Jia; David Jones; Henry Knott; Chai Yin Kok; King Wai Lau; Catherine Leroy; Meng-Lay Lin; David J McBride; Mark Maddison; Simon Maguire; Kirsten McLay; Andrew Menzies; Tatiana Mironenko; Lee Mulderrig; Laura Mudie; Sarah O'Meara; Erin Pleasance; Arjunan Rajasingham; Rebecca Shepherd; Raffaella Smith; Lucy Stebbings; Philip Stephens; Gurpreet Tang; Patrick S Tarpey; Kelly Turrell; Karl J Dykema; Sok Kean Khoo; David Petillo; Bill Wondergem; John Anema; Richard J Kahnoski; Bin Tean Teh; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2010-01-06       Impact factor: 49.962

  7 in total
  2 in total

Review 1.  [Focal therapy for small renal masses : Observation, ablation or surgery].

Authors:  J J Wendler; B Friebe; D Baumunk; A Blana; T Franiel; R Ganzer; B Hadaschik; T Henkel; K U Köhrmann; J Köllermann; T Kuru; S Machtens; A Roosen; G Salomon; H P Schlemmer; L Sentker; U Witzsch; U B Liehr; J Ricke; M Schostak
Journal:  Urologe A       Date:  2016-05       Impact factor: 0.639

2.  Histologic Heterogeneity of Extirpated Renal Cell Carcinoma Specimens: Implications for Renal Mass Biopsy.

Authors:  Lauren M Nahouraii; Jordan L Allen; Suzanne B Merrill; Erik Lehman; Matthew G Kaag; Jay D Raman
Journal:  J Kidney Cancer VHL       Date:  2020-08-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.